Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Camostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.61 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.61 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.61 |
| ▸ | KLK1 | P06870 | 4/20 | 0.61 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.61 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.61 |
| ▸ | F2 | P00734 | 2/20 | 0.61 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.61 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.61 |
| ▸ | HPN | P05981 | 1/20 | 0.61 |
| ▸ | CTSL | P07711 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.61 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.61 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.61 |
| ▸ | KLK7 | P49862 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camostat SCHEMBL1648303 | 0.99 | PRSS1 (0.62) | PRSS1KLK1PRSS2PRSS3F2 | |
| Camostat SCHEMBL8829828 | 0.94 | PRSS1 (0.66) | PRSS1KLK1PRSS2PRSS3F2 | |
| SCHEMBL20008640 | 0.94 | PRSS1 (0.68) | PRSS1KLK1PRSS2PRSS3F2 | |
| Camostat SCHEMBL125269 | 0.94 | PRSS1 (0.68) | PRSS1KLK1PRSS2PRSS3F2 | |
| Camostat SCHEMBL1646099 | 0.94 | PRSS1 (0.62) | PRSS1KLK1PRSS2PRSS3F2 | |
| Camostat SCHEMBL2326660 | 0.94 | PRSS1 (0.62) | PRSS1KLK1PRSS2PRSS3F2 | |
| Camostat SCHEMBL1645380 | 0.93 | PRSS1 (0.64) | PRSS1KLK1PRSS2PRSS3F2 | |
| Camostat SCHEMBL2782237 | 0.93 | PRSS1 (0.67) | PRSS1KLK1PRSS2PRSS3F2 | |
| Camostat SCHEMBL1646391 | 0.92 | PRSS1 (0.60) | PRSS1KLK1PRSS2PRSS3F2 | |
| Camostat SCHEMBL1648218 | 0.92 | PRSS1 (0.60) | PRSS1KLK1PRSS2PRSS3F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253612-A1 | Organic compounds | Novartis AG (CH) | 2010-11-24 | — | — | EP | claimed |
| US-20090203777-A1 | ORGANIC COMPOUNDS | MAAS, JANET CATHERINE (GB) | 2009-08-13 | — | — | US | claimed |
| EP-1874726-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-01-09 | — | — | EP | claimed |
| WO-2006108643-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | claimed |
| WO-2021255218-A1 | A PHARMACEUTICAL COMBINATION COMPRISING AN ANTI-VIRAL PROTONOPHORE AND A SERINE PROTEASE INHIBITOR | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2021-12-23 | — | — | WO | disclosed |
| US-20120208882-A1 | Organic Compounds | DANAHAY HENRY LUKE (GB) | 2012-08-16 | — | — | US | disclosed |
| EP-2305639-A2 | Organic compounds | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-2253612-A1 | Organic compounds | Novartis AG (CH) | 2010-11-24 | — | — | EP | disclosed |
| US-20090203777-A1 | ORGANIC COMPOUNDS | MAAS, JANET CATHERINE (GB) | 2009-08-13 | — | — | US | disclosed |
| EP-1874726-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108643-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208882-A1 | Organic Compounds | CFTR, OTC, ASIC1 | ADRA1A 1617/4885OPRD1 626/4885MEN1 4069/4885 |
| US-20090203777-A1 | ORGANIC COMPOUNDS | CFTR, OTC, ASIC1 | ADRA1A 1617/4885OPRD1 626/4885MEN1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.